Published 1 day ago • loading... • Updated 1 day agoShow Less IconInhibrx cancer therapy outperforms Merck’s Keytruda (INBX:NASDAQ) Summary by Seeking AlphaInhibrx Biosciences (INBX) stock gains as cancer therapy INBRX-106 with Merck (MRK) Keytruda outperforms the blockbuster drug in a mid-stage trial. Read more here.Share menu1 Articles1 ArticlesAllLeftCenterRight1Search IconSort IconSeeking AlphaLean RightFactualityOwnershipInhibrx cancer therapy outperforms Merck’s Keytruda (INBX:NASDAQ)Inhibrx Biosciences (INBX) stock gains as cancer therapy INBRX-106 with Merck (MRK) Keytruda outperforms the blockbuster drug in a mid-stage trial. Read more here.1 day ago·Ra'anana, IsraelRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left0Leaning Right1Center0Last Updated1 day agoBias Distribution100% RightBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources lean Right100% RightR 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageSeeking Alpha broke the news in Ra'anana, Israel 1 day ago on Tuesday, September 8, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsMerck Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsMerck Plus IconShow All